Get the Stockscreener App
1.94
5.88%
-0.10
After Hours:
1.90
-0.04
-2.06%
Cero Therapeutics Holdings Inc stock is traded at $1.94, with a volume of 160.61K.
It is down -5.88% in the last 24 hours and down -63.29% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
See More
Previous Close:
$2.04
Open:
$1.96
24h Volume:
160.61K
Relative Volume:
0.15
Market Cap:
$5.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.28%
1M Performance:
-63.29%
6M Performance:
-84.81%
1Y Performance:
+0.00%
1-Day Range:
$1.90
$2.13
1-Week Range:
$1.77
$2.22
52-Week Range:
$1.76
$1,095.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
1.94 | 5.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
CERo Therapeutics to raise $5M via ATM offering - MSN
CERo Therapeutics strengthens cash reserves, advances clinical trials By Investing.com - Investing.com Nigeria
CERo Therapeutics strengthens cash reserves, advances clinical trials - MSN
Cero Therapeutics prices $5M at-the-market offering - MSN
CERo Therapeutics Holdings, Inc. Highlights Progress - GlobeNewswire
Major Cancer Treatment Breakthrough: CERo's Next-Gen Therapy Heads to Clinical Trials with Fresh Funding - StockTitan
ForexTV | Small Business Resources - ForexTV.com
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - The Manila Times
CERo's Strategic $5M Capital Raise Draws Insider Investment - StockTitan
Cero Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Marketscreener.com
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
Troy Minerals Expands Table Mountain Silica Project - The Globe and Mail
CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Down 97.9% in January - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CERO Therapeutics secures NASDAQ compliance extension - Investing.com India
CERO stock touches 52-week low at $2.83 amid steep annual decline - Investing.com Nigeria
3 Retail Stocks That Will Ring the Register in 2025 - The Globe and Mail
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer - Marketscreener.com
CERo Therapeutics : Amendments to Bylaws Form 8 K - Marketscreener.com
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer - Marketscreener.com
CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Chris Ehrlich CEO - Marketscreener.com
CERo Therapeutics Holdings, Inc. Appoints Kristen Pierce as Chief Development Officer - Marketscreener.com
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
CERo Therapeutics Holdings, Inc. Announces CEO Changes - Marketscreener.com
CERo Therapeutics (NASDAQ:CERO) Hits New 12-Month LowTime to Sell? - MarketBeat
CERo Therapeutics to implement reverse stock split - MSN
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - The Manila Times
CERo Therapeutics Announces 1:100 Reverse Stock Split to Avoid Nasdaq Delisting - StockTitan
CERO stock plunges to 52-week low, touches $0.05 - Investing.com
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Cero Therapeutics holdings sees $400,456 in stock sales by YK Bioventures - Investing.com Australia
Cero Therapeutics sees $383,369 in stock sales by YK Bioventures - Investing.com Australia
CERo Therapeutics appoints Chris Ehrlich CEO - MSN
Where Will SoFi Stock Be in 2025? - The Globe and Mail
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
CERo Therapeutics Names Chris Ehrlich Permanent CEO, Advances Novel Cancer Treatment Pipeline - StockTitan
Cero therapeutics investor Sloan Stuart sells $55,538 in stock By Investing.com - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN
CERo Therapeutics Holdings Inc. (CERO) reports earnings - Quartzy
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cero Therapeutics Holdings Inc Stock (CERO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):